{
  "meta": {
    "title": "44_Raas_Ace_Arbs",
    "url": "https://brainandscalpel.vercel.app/44-raas-ace-arbs-2d4e233c.html",
    "scrapedAt": "2025-11-30T07:00:00.656Z"
  },
  "questions": [
    {
      "id": 50198,
      "choices": [
        {
          "id": 248337,
          "text": "ARB"
        },
        {
          "id": 248338,
          "text": "Calcium channel blocker"
        },
        {
          "id": 248339,
          "text": "Thiazide Diuretics"
        },
        {
          "id": 248340,
          "text": "Beta Blockers"
        }
      ],
      "text": "According to JNC VIII Criteria, Initial antihypertensive treatment in population aged 18 years or older with CKD and hypertension is",
      "unique_key": "Q1416211",
      "question_audio": null,
      "question_video": null,
      "map_id": 34422833,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) ARB. According to the JNC 8 (Eighth Joint National Committee) guidelines, the initial antihypertensive treatment for individuals aged 18 years or older with chronic kidney disease (CKD) and hypertension is recommended to be an angiotensin II receptor blocker (ARB) or an ACE inhibitor. This recommendation is based on the evidence that ACE inhibitors and ARBs help reduce proteinuria and protect kidney function in CKD patients by blocking the effects of angiotensin II, which can be harmful to the kidneys. These medications also lower blood pressure, which is crucial for slowing the progression of kidney disease. Explanation for incorrect options: Option B: Calcium channel blocker – Calcium channel blockers (CCBs) are effective for blood pressure management, but they are not the first-line therapy for hypertension in CKD patients according to JNC 8 guidelines. ARBs or ACE inhibitors are preferred as they offer additional kidney protection by targeting angiotensin II. While CCBs may be used as add-on therapy, they are not the first choice for CKD patients. Option C: Thiazide Diuretics – Thiazide diuretics are generally used as first-line therapy for hypertension in individuals without CKD. However, in patients with CKD and hypertension, they may be less effective, especially if glomerular filtration rate (GFR) is reduced. The ARB or ACE inhibitor is preferred due to its specific kidney-protective effects. Option D: Beta Blockers – Beta blockers are used for hypertension and can be helpful in certain conditions (e.g., heart failure, post-myocardial infarction), but they are not the preferred initial treatment for hypertension in CKD patients. They do not offer the same renal protection as ACE inhibitors or ARBs.",
      "correct_choice_id": 248337,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36904561698479451/36904561698479451.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36904561698479451/36904561698479451.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50199,
      "choices": [
        {
          "id": 248341,
          "text": "ARB"
        },
        {
          "id": 248342,
          "text": "Calcium channel blocker"
        },
        {
          "id": 248343,
          "text": "ACE inhibitor"
        },
        {
          "id": 248344,
          "text": "Beta Blockers"
        }
      ],
      "text": "According to JNC VIII Criteria, Initial antihypertensive treatment in general black population, including those with diabetes is",
      "unique_key": "Q1942034",
      "question_audio": null,
      "question_video": null,
      "map_id": 34245476,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Calcium channel blocker. According to the JNC 8 (Eighth Joint National Committee) guidelines, calcium channel blockers (CCBs) are the preferred initial antihypertensive treatment for the general black population, including those with diabetes. This recommendation is based on evidence that CCBs are effective in reducing blood pressure and have been shown to provide more favorable outcomes in this demographic compared to other classes of antihypertensive medications. Additionally, CCBs are effective at treating hypertension without significantly affecting glucose metabolism, which is important for individuals with diabetes. Explanation for incorrect options: Option A: ARB – Angiotensin II receptor blockers (ARBs) are effective for treating hypertension and protecting kidney function, especially in individuals with chronic kidney disease (CKD). However, the JNC 8 guidelines recommend CCBs as the initial therapy for the general black population with hypertension, as they have been shown to be more effective in this group compared to ARBs. Option C: ACE inhibitor – ACE inhibitors are an important class of drugs for managing hypertension and have renoprotective effects, especially in individuals with diabetes. However, ACE inhibitors are not the first-line treatment for the general black population according to the JNC 8 guidelines. In this population, CCBs are considered more effective for initial treatment. Option D: Beta Blockers – Beta blockers are useful in certain conditions, such as heart failure and post-myocardial infarction, but they are not recommended as first-line therapy for the general black population with hypertension, according to JNC 8. Studies have shown that CCBs are more effective in reducing blood pressure in this group compared to beta blockers.",
      "correct_choice_id": 248342,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50200,
      "choices": [
        {
          "id": 248345,
          "text": "Fosinopril"
        },
        {
          "id": 248346,
          "text": "Enalapril"
        },
        {
          "id": 248347,
          "text": "Ramipril"
        },
        {
          "id": 248348,
          "text": "Lisinopril"
        }
      ],
      "text": "Which of the following ACE inhibitor is NOT a prodrug",
      "unique_key": "Q5981269",
      "question_audio": null,
      "question_video": null,
      "map_id": 34034409,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Lisinopril. Lisinopril is unique among ACE inhibitors because it is not a prodrug—it is administered in its active form and does not require metabolic activation in the liver. Most ACE inhibitors are prodrugs, meaning they need to be converted in the liver to their active forms. Lisinopril, however, is hydrophilic and has a long half-life, allowing it to be directly absorbed and utilized without hepatic conversion. This characteristic makes it particularly useful in patients with hepatic impairment since it does not require liver metabolism to become active. Explanation for incorrect responses: Option A: Fosinopril – Prodrug Fosinopril is a prodrug that must be converted into fosinoprilat in the liver to exert its ACE-inhibitory effects. Unlike other ACE inhibitors, it is primarily excreted through both renal and hepatic routes, making it an alternative for patients with renal impairment. Option B: Enalapril – Prodrug Enalapril is another prodrug that requires conversion in the liver to its active form, enalaprilat. Enalapril itself has low bioavailability, but once metabolized, enalaprilat effectively inhibits the angiotensin-converting enzyme (ACE). Option C: Ramipril – Prodrug Ramipril is a prodrug that is metabolized in the liver to its active form, ramiprilat. It is known for its long-lasting effects and cardiovascular benefits, especially in high-risk patients.",
      "correct_choice_id": 248348,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14115701698479734/14115701698479734.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/14115701698479734/14115701698479734.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50201,
      "choices": [
        {
          "id": 248349,
          "text": "Losartan"
        },
        {
          "id": 248350,
          "text": "Candisartan"
        },
        {
          "id": 248351,
          "text": "Telmesartan"
        },
        {
          "id": 248352,
          "text": "Eprosartan"
        }
      ],
      "text": "Angiotensin receptor blocker with additional PPAR-r-agonist activity is",
      "unique_key": "Q8363502",
      "question_audio": null,
      "question_video": null,
      "map_id": 34443739,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Telmisartan Telmisartan is an angiotensin II receptor blocker (ARB) that uniquely functions as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR-γ). This PPAR-γ agonist activity contributes to its additional metabolic benefits, such as improving insulin sensitivity and reducing the risk of type 2 diabetes mellitus. These properties make telmisartan particularly beneficial for hypertensive patients with metabolic syndrome or diabetes. Incorrect Responses A. Losartan Losartan is an ARB that primarily blocks the AT1 receptor to lower blood pressure. While some studies suggest that certain ARBs may exhibit PPAR-γ agonist activity, losartan's effect is relatively weak compared to telmisartan. Therefore, it is not considered a significant PPAR-γ agonist. B. Candesartan Candesartan is another ARB effective in managing hypertension. However, it does not possess notable PPAR-γ agonist activity. Its primary mechanism involves selective AT1 receptor antagonism without significant interaction with PPAR-γ receptors. D. Eprosartan Eprosartan is an ARB that effectively inhibits the AT1 receptor. There is no substantial evidence to suggest that eprosartan has PPAR-γ agonist activity. Its therapeutic effects are mainly attributed to its action on the renin-angiotensin system.",
      "correct_choice_id": 248351,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63039251698479748/63039251698479748.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63039251698479748/63039251698479748.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50202,
      "choices": [
        {
          "id": 248353,
          "text": "Inhabitation of cytoskeletal rearrangements"
        },
        {
          "id": 248354,
          "text": "Inhabitation of retraction of podocyte processes"
        },
        {
          "id": 248355,
          "text": "Inhabitation of reduction in proteins of the slit diaphragm"
        },
        {
          "id": 248356,
          "text": "All of the above"
        }
      ],
      "text": "ACE inhibitor decrease renal micralbumuruia by following mechanism",
      "unique_key": "Q9604608",
      "question_audio": null,
      "question_video": null,
      "map_id": 34606758,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Explanation: ACE inhibitors reduce renal microalbuminuria through multiple mechanisms that help protect the glomerular filtration barrier. These mechanisms include: Inhibition of cytoskeletal rearrangements – ACE inhibitors prevent changes in the actin cytoskeleton of podocytes, which helps maintain the structural integrity of the glomerular filtration barrier. Inhibition of retraction of podocyte processes – ACE inhibitors help stabilize podocyte foot processes, preventing their detachment and reducing protein leakage into the urine. Inhibition of reduction in proteins of the slit diaphragm – ACE inhibitors preserve slit diaphragm proteins (e.g., nephrin, podocin) that are crucial for maintaining the selective permeability of the glomerulus. By combining these effects, ACE inhibitors reduce microalbuminuria and slow the progression of diabetic nephropathy and other chronic kidney diseases. Explanation for incorrect options: Option A: Inhibition of cytoskeletal rearrangements – This is correct, but it is only one of the mechanisms through which ACE inhibitors work. Option B: Inhibition of retraction of podocyte processes – Also correct, but not the sole mechanism. Option C: Inhibition of reduction in proteins of the slit diaphragm – Correct, but alone does not fully explain the protective effects.",
      "correct_choice_id": 248356,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50203,
      "choices": [
        {
          "id": 248357,
          "text": "Telmisartan"
        },
        {
          "id": 248358,
          "text": "Candesartan"
        },
        {
          "id": 248359,
          "text": "Olmesartan"
        },
        {
          "id": 248360,
          "text": "Losartan"
        }
      ],
      "text": "A metabolite of an ARB reducing COX-2 mRNA up regulation among the following is",
      "unique_key": "Q2087576",
      "question_audio": null,
      "question_video": null,
      "map_id": 34757714,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Losartan. Losartan is an angiotensin II receptor blocker (ARB) that undergoes metabolism in the liver to form an active metabolite, EXP3179. This metabolite has been shown to reduce COX-2 mRNA upregulation, thereby modulating inflammation and reducing prostaglandin synthesis. Since COX-2 is an enzyme involved in inflammation and vascular homeostasis, this effect may contribute to additional cardiovascular and renal protection beyond the ARB activity of losartan. Incorrect Options: Option A: Telmisartan – While telmisartan is an ARB with additional PPAR-γ agonist activity, it does not specifically inhibit COX-2 mRNA upregulation like losartan's EXP3179 metabolite. Option B: Candesartan – Candesartan is a potent ARB but lacks the active metabolite (EXP3179) responsible for COX-2 mRNA inhibition seen with losartan. Option C: Olmesartan – Similar to candesartan, olmesartan does not produce an active metabolite that affects COX-2 regulation.",
      "correct_choice_id": 248360,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50204,
      "choices": [
        {
          "id": 248361,
          "text": "Olmesertan"
        },
        {
          "id": 248362,
          "text": "Irbesartan"
        },
        {
          "id": 248363,
          "text": "Telmisartan"
        },
        {
          "id": 248364,
          "text": "Losartan"
        }
      ],
      "text": "ARB having highest affinity for AT1 receptor among the following is",
      "unique_key": "Q4064523",
      "question_audio": null,
      "question_video": null,
      "map_id": 34760297,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Olmesartan Olmesartan has the highest affinity for the angiotensin II type 1 (AT1) receptor among the angiotensin receptor blockers (ARBs) listed. The AT1 receptor is responsible for mediating the effects of angiotensin II, such as vasoconstriction, sodium retention, and aldosterone secretion. By strongly blocking AT1 receptors, olmesartan provides potent and long-lasting antihypertensive effects. It has a higher binding affinity compared to other ARBs, leading to a more sustained blockade of the renin-angiotensin system (RAS). Incorrect Options: (B) Irbesartan – Irbesartan has a moderate affinity for AT1 receptors, but it is lower than olmesartan. It has a longer half-life and provides good blood pressure control, but its receptor affinity is not the highest. (C) Telmisartan – Telmisartan is unique because of its PPAR-γ agonist activity, which provides additional metabolic benefits. However, its AT1 receptor affinity is lower than olmesartan. (D) Losartan – Losartan has the lowest affinity among the options listed. It also undergoes metabolism to form an active metabolite (EXP3174), which contributes to its ARB effects, but its direct binding affinity for AT1 receptors is weaker than olmesartan.",
      "correct_choice_id": 248361,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60627781698479768/60627781698479768.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60627781698479768/60627781698479768.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50205,
      "choices": [
        {
          "id": 248365,
          "text": "Telmisartan"
        },
        {
          "id": 248366,
          "text": "Olmesertan"
        },
        {
          "id": 248367,
          "text": "Losartan"
        },
        {
          "id": 248368,
          "text": "Irbesartan"
        }
      ],
      "text": "A patient with gout needs to be started in an ARB, which one of them is best to this patient",
      "unique_key": "Q1002052",
      "question_audio": null,
      "question_video": null,
      "map_id": 34613157,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Losartan Losartan is the preferred ARB for a patient with gout because it has a unique uricosuric effect, meaning it helps lower serum uric acid levels. Unlike other ARBs, losartan inhibits urate transporter 1 (URAT1) in the kidneys, leading to increased uric acid excretion in urine and reduced serum uric acid levels. This makes it an ideal choice for hypertensive patients who also have gout, as it can help prevent gout flares while controlling blood pressure. Incorrect Options: (A) Telmisartan – While telmisartan is a potent ARB and has additional PPAR-γ agonist activity, which provides metabolic benefits, it does not have a uricosuric effect and does not lower uric acid levels. (B) Olmesartan – Olmesartan is a strong AT1 receptor blocker but does not promote uric acid excretion. It may actually increase uric acid levels in some patients. (D) Irbesartan – Irbesartan is effective for hypertension and diabetic nephropathy, but it lacks the uricosuric effect seen with losartan. It does not significantly affect uric acid excretion.",
      "correct_choice_id": 248367,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77019571698479784/77019571698479784.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77019571698479784/77019571698479784.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50206,
      "choices": [
        {
          "id": 248369,
          "text": "Amidases"
        },
        {
          "id": 248370,
          "text": "Esterases"
        },
        {
          "id": 248371,
          "text": "Angiotensin converting enzyme"
        },
        {
          "id": 248372,
          "text": "Conjugases"
        }
      ],
      "text": "Enzymes activating prodrugs of ACE inhibitors of active form is",
      "unique_key": "Q6659920",
      "question_audio": null,
      "question_video": null,
      "map_id": 34355846,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Esterases Most ACE inhibitors are administered as prodrugs and require activation to exert their pharmacological effects. Esterases are the key enzymes responsible for converting these inactive prodrugs into their active forms. This activation occurs primarily in the liver and involves the hydrolysis of ester bonds, which transforms the prodrug into the active diacid form that inhibits angiotensin-converting enzyme (ACE). Incorrect Options: (A) Amidases – Amidases break down amide bonds rather than ester bonds. They are not primarily involved in the activation of ACE inhibitor prodrugs. (C) Angiotensin-converting enzyme (ACE) – ACE is the target enzyme inhibited by active ACE inhibitors, but it does not participate in their activation. (D) Conjugases – These enzymes are involved in phase II metabolism, such as glucuronidation or sulfation, but they do not activate prodrugs of ACE inhibitors.",
      "correct_choice_id": 248370,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50207,
      "choices": [
        {
          "id": 248373,
          "text": "Enalapril"
        },
        {
          "id": 248374,
          "text": "Lisinorpril"
        },
        {
          "id": 248375,
          "text": "Ramipril"
        },
        {
          "id": 248376,
          "text": "Perindopril"
        }
      ],
      "text": "Among the following ACE inhibitor with Longest half-life is",
      "unique_key": "Q4173515",
      "question_audio": null,
      "question_video": null,
      "map_id": 34145731,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Perindopril Explanation: Among ACE inhibitors, Perindopril has the longest half-life due to its pharmacokinetic properties. Perindopril is a prodrug, which gets converted into its active metabolite Perindoprilat. The elimination half-life of Perindoprilat is around 25-30 hours, allowing for once-daily dosing and sustained ACE inhibition. This prolonged effect makes it particularly beneficial for long-term blood pressure control and cardiovascular protection. Explanation for Incorrect Options: (A) Enalapril – Enalapril is also a prodrug, converted into Enalaprilat, which has a half-life of around 11 hours. While it has a moderate duration of action, it is shorter than Perindopril. (B) Lisinopril – Lisinopril is not a prodrug and has a half-life of approximately 12 hours. It is often given once daily, but its duration of action is still shorter than Perindopril. (C) Ramipril – Ramipril, another prodrug, gets converted into Ramiprilat, which has a half-life of 13-17 hours. While longer than Enalapril and Lisinopril, it is not as prolonged as Perindopril.",
      "correct_choice_id": 248376,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50208,
      "choices": [
        {
          "id": 248377,
          "text": "Captopril"
        },
        {
          "id": 248378,
          "text": "Clonidine"
        },
        {
          "id": 248379,
          "text": "Labetalol"
        },
        {
          "id": 248380,
          "text": "Methyldopa"
        }
      ],
      "text": "A patient who has been taking an oral antihypertensive drug for about a year develops a positive Coomb’s test. Which of the following is the most likely cause?",
      "unique_key": "Q8809987",
      "question_audio": null,
      "question_video": null,
      "map_id": 34836602,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Methyldopa. Methyldopa is a centrally acting β1-adrenergic agonist used in the treatment of hypertension, particularly in pregnant women. One of its significant adverse effects is drug-induced hemolytic anemia, which occurs due to the production of autoantibodies against red blood cells (RBCs). This leads to a positive Coombs test, which detects autoimmune hemolysis. The direct Coombs test (direct antiglobulin test, DAT) identifies IgG or complement proteins bound to RBCs, confirming the presence of immune-mediated hemolysis. Methyldopa-induced hemolysis is dose-dependent, with higher doses increasing the risk. While many patients with a positive Coombs test remain asymptomatic, some may develop hemolytic anemia, requiring discontinuation of methyldopa. Explanation of Incorrect Options: (A) Captopril – Incorrect. Captopril is an ACE inhibitor that does not cause Coombs-positive hemolytic anemia. Its common adverse effects include cough, angioedema, hyperkalemia, and hypotension, but it does not trigger autoimmune hemolysis. (B) Clonidine Clonidine is another centrally acting β1-agonist, like methyldopa, but it does not cause hemolytic anemia. Instead, it can cause rebound hypertension if suddenly discontinued, along with sedation, dry mouth, and bradycardia. (C) Labetalol Labetalol is a nonselective β-blocker and α3-blocker used for hypertension, including hypertensive emergencies and pregnancy-related hypertension. While it can cause hypotension, dizziness, and bradycardia, it is not associated with autoimmune hemolytic anemia.",
      "correct_choice_id": 248380,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12869901700305154/12869901700305154.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12869901700305154/12869901700305154.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50209,
      "choices": [
        {
          "id": 248381,
          "text": "Atorvastatin"
        },
        {
          "id": 248382,
          "text": "Captopril"
        },
        {
          "id": 248383,
          "text": "Labetalol"
        },
        {
          "id": 248384,
          "text": "Verapamil"
        }
      ],
      "text": "A 52-year-old woman with essential hypertension, hypercholesterolemia, and chronic-stable angina develops severe constipation. It is attributed to one of her medications. Which was the most likely cause?",
      "unique_key": "Q2790124",
      "question_audio": null,
      "question_video": null,
      "map_id": 34157665,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Verapamil. Verapamil is a non-dihydropyridine calcium channel blocker (CCB) used to treat hypertension, angina, and certain arrhythmias (e.g., atrial fibrillation). One of its most common side effects is constipation, which occurs due to its inhibitory effect on intestinal smooth muscle contraction, leading to delayed colonic transit. This side effect is more pronounced with verapamil than with other calcium channel blockers like diltiazem or dihydropyridines (e.g., amlodipine, nifedipine). Other side effects of verapamil include bradycardia, hypotension, AV block, and gingival hyperplasia. Given this patient’s history of hypertension, hypercholesterolemia, and chronic-stable angina, verapamil was likely prescribed for blood pressure control and angina relief. Explanation of Incorrect Options: (A) Atorvastatin Atorvastatin is a HMG-CoA reductase inhibitor (statin) used to lower cholesterol. While it can cause myopathy and hepatotoxicity, it is not a common cause of severe constipation. Statins may cause mild gastrointestinal discomfort, but they do not directly affect intestinal motility like verapamil. (B) Captopril Captopril is an ACE inhibitor commonly used for hypertension and heart failure. Its adverse effects include cough (due to bradykinin accumulation), angioedema, hyperkalemia, and hypotension, but it does not cause constipation. (C) Labetalol Labetalol is a nonselective β-blocker and α1-blocker used for hypertension, including hypertensive emergencies and pregnancy-induced hypertension. Its side effects include bradycardia, dizziness, fatigue, and orthostatic hypotension, but it is not a significant cause of constipation.",
      "correct_choice_id": 248384,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61707031700305170/61707031700305170.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61707031700305170/61707031700305170.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50210,
      "choices": [
        {
          "id": 248385,
          "text": "Blood pressure would rise abruptly"
        },
        {
          "id": 248386,
          "text": "Better BP control, but with a risk of hyperkalemia"
        },
        {
          "id": 248387,
          "text": "Cardiac depression, because both drugs directly depress the heart"
        },
        {
          "id": 248388,
          "text": "Cough that may be severe, even though there was no cough with lisinopril alone"
        }
      ],
      "text": "A hypertensive patient has been on long-term therapy with lisinopril. The drug isn’t controlling pressure as well as wanted, so the physician decides to add triamterene as the second drug. What is the most likely outcome of adding this diuretic to the ACE inhibitor regimen?",
      "unique_key": "Q8033904",
      "question_audio": null,
      "question_video": null,
      "map_id": 34456528,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Better BP control, but with a risk of hyperkalemia. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, which lowers blood pressure by reducing angiotensin II levels and decreasing aldosterone secretion. This leads to reduced sodium and water retention but also causes potassium retention, increasing the risk of hyperkalemia. Triamterene is a potassium-sparing diuretic that works by blocking epithelial sodium channels (ENaC) in the distal tubule and collecting duct, leading to increased sodium excretion while retaining potassium. When combined with lisinopril, the effect of potassium retention is enhanced, significantly increasing the risk of hyperkalemia, which can lead to life-threatening cardiac arrhythmias. This combination is often used cautiously in clinical practice for better blood pressure control, but potassium levels must be monitored closely. Explanation of Incorrect Options: (A) Blood pressure would rise abruptly – Incorrect. Adding triamterene to lisinopril enhances BP control rather than causing an abrupt rise. Triamterene itself has a mild antihypertensive effect, and it does not oppose the action of ACE inhibitors. (C) Cardiac depression, because both drugs directly depress the heart – Incorrect. Neither lisinopril nor triamterene directly depress cardiac contractility. Lisinopril reduces afterload by dilating blood vessels, and triamterene mainly affects renal sodium and potassium handling, not the heart’s contractile function. (D) Cough that may be severe, even though there was no cough with lisinopril alone – Incorrect. ACE inhibitors like lisinopril can cause a dry cough due to increased bradykinin levels, but triamterene does not affect bradykinin metabolism. If a patient did not develop a cough with lisinopril alone, adding triamterene would not trigger it.",
      "correct_choice_id": 248386,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23726781700305207/23726781700305207.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23726781700305207/23726781700305207.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50211,
      "choices": [
        {
          "id": 248389,
          "text": "Captopril"
        },
        {
          "id": 248390,
          "text": "Guanethidine"
        },
        {
          "id": 248391,
          "text": "Minoxidil"
        },
        {
          "id": 248392,
          "text": "Prazosin"
        }
      ],
      "text": "A friend has very severe hypertension and asks about a drug her doctor wishes to prescribe. Her physician has explained that this drug is associated with tachycardia and fluid retention (which may be marked) and increased hair growth. Which of the following is most likely to produce the effects that your friend has described?",
      "unique_key": "Q9252434",
      "question_audio": null,
      "question_video": null,
      "map_id": 34997473,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Minoxidil. Minoxidil is a potent direct vasodilator that works by opening ATP-sensitive potassium channels in vascular smooth muscle, leading to arteriolar vasodilation. This results in a significant decrease in blood pressure. However, the sudden reduction in vascular resistance triggers compensatory reflex mechanisms, leading to: Reflex tachycardia – Due to baroreceptor activation, causing increased sympathetic outflow. Fluid retention – As a response to decreased BP, the renin-angiotensin-aldosterone system (RAAS) is activated, leading to sodium and water retention, which can cause edema and even heart failure. Hypertrichosis (excessive hair growth) – Minoxidil was initially developed as an antihypertensive, but its side effect of hair growth led to its use in treating androgenic alopecia (male and female pattern baldness). Because of these effects, minoxidil is usually given with a β-blocker (to control tachycardia) and a loop diuretic (to counteract fluid retention). Explanation of Incorrect Options: (A) Captopril – Incorrect. Captopril is an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II formation, leading to vasodilation and reduced fluid retention. Unlike minoxidil, it does not cause tachycardia (since it does not trigger a strong reflex sympathetic response) and does not promote hair growth. (B) Guanethidine – Incorrect. Guanethidine is a sympatholytic agent that lowers BP by depleting norepinephrine from nerve terminals. While it can cause fluid retention, it typically causes bradycardia (not tachycardia) and has no effect on hair growth. (D) Prazosin – Incorrect. Prazosin is an α1-blocker, which also lowers blood pressure by vasodilation. However, it causes less reflex tachycardia than minoxidil. It does not cause fluid retention as severely as minoxidil, and it does not cause hair growth.",
      "correct_choice_id": 248391,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64275591700305224/64275591700305224.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64275591700305224/64275591700305224.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50212,
      "choices": [
        {
          "id": 248393,
          "text": "Ramipril"
        },
        {
          "id": 248394,
          "text": "Atenolol"
        },
        {
          "id": 248395,
          "text": "Cilnidipine"
        },
        {
          "id": 248396,
          "text": "Clonidine"
        }
      ],
      "text": "A 62 year old female patient who is known case of mild CKD comes to with BP of 160/96. There is no history of Diabetes mellitus and CHF. Which anti hypertensive is the best to start in this patient?",
      "unique_key": "Q3296546",
      "question_audio": null,
      "question_video": null,
      "map_id": 34355139,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ramipril. Ramipril is an ACE inhibitor that is commonly used in patients with chronic kidney disease (CKD), especially those with mild CKD. ACE inhibitors have several advantages in these patients: Renal protection: ACE inhibitors help reduce proteinuria and provide kidney protection, which is particularly important in CKD. They lower glomerular pressure and reduce the progression of kidney damage by dilating the efferent arteriole of the glomerulus. Blood pressure control: They are effective in lowering blood pressure, which can prevent the progression of kidney disease and reduce cardiovascular risk. No impact on glucose metabolism: Since this patient has no history of diabetes, ACE inhibitors are beneficial because they do not negatively impact glucose metabolism. Thus, ramipril is an ideal choice for this patient with mild CKD and hypertension. Explanation of Incorrect Options: (B) Atenolol Atenolol is a β1-blocker. While it can be used in hypertension, it is less preferred in CKD compared to ACE inhibitors. β-blockers do not provide specific renal protection and may also be less effective in younger patients. Additionally, atenolol has limited benefits for proteinuria reduction or slowing progression of CKD. It may also have metabolic effects, such as increasing insulin resistance in some patients. (C) Cilnidipine Cilnidipine is a calcium channel blocker (CCB), which works by relaxing vascular smooth muscle to lower blood pressure. While it is effective in treating hypertension, CCBs do not provide the same level of renal protection as ACE inhibitors do. They also do not have the beneficial effects on proteinuria seen with ACE inhibitors. Cilnidipine can be an option if ACE inhibitors are contraindicated, but it is not the first choice in CKD. (D) Clonidine Clonidine is an α2-adrenergic agonist that lowers blood pressure by reducing sympathetic tone. While it can be used in hypertension, it is not a first-line agent for the management of hypertension in CKD. It can cause sedation, dry mouth, and rebound hypertension upon discontinuation. Additionally, it does not provide renal protection and is not recommended for routine use in CKD.",
      "correct_choice_id": 248393,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3769811700305236/3769811700305236.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3769811700305236/3769811700305236.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50213,
      "choices": [
        {
          "id": 248397,
          "text": "Decrease in renin level"
        },
        {
          "id": 248398,
          "text": "Inhibition of the angiotensin-converting enzyme"
        },
        {
          "id": 248399,
          "text": "Inhibition of calcium channels"
        },
        {
          "id": 248400,
          "text": "Increased excretion of sodium and water"
        }
      ],
      "text": "What is the primary mechanism of action of ACE inhibitors?",
      "unique_key": "Q2304218",
      "question_audio": null,
      "question_video": null,
      "map_id": 34727643,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Inhibition of the angiotensin-converting enzyme. ACE inhibitors, such as enalapril, lisinopril, and ramipril, work by blocking the angiotensin-converting enzyme (ACE), which is responsible for converting angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor and stimulates aldosterone release, leading to sodium and water retention. By inhibiting ACE, these drugs cause vasodilation, reduced blood pressure, and decreased afterload, making them highly effective in treating hypertension, heart failure, and chronic kidney disease. Additionally, ACE inhibitors enhance bradykinin levels, which further contributes to vasodilation but can also lead to side effects like cough and angioedema. Explanation of Incorrect Options: (A) Decrease in renin level – Incorrect. ACE inhibitors do not decrease renin levels; in fact, they can cause a compensatory increase in renin release due to the loss of negative feedback from angiotensin II. Renin is secreted by the kidneys in response to low blood pressure or sodium levels, and its increase helps maintain blood pressure when ACE is inhibited. (C) Inhibition of calcium channels – Incorrect. ACE inhibitors do not block calcium channels. Calcium channel blockers (CCBs) like amlodipine or verapamil work by preventing calcium influx into vascular smooth muscle and cardiac cells, leading to vasodilation and reduced myocardial contractility. However, this mechanism is distinct from the renin-angiotensin-aldosterone system (RAAS) inhibition seen with ACE inhibitors. (D) Increased excretion of sodium and water – Incorrect. While ACE inhibitors can lead to natriuresis (sodium excretion) and diuresis (water loss), this is an indirect effect due to reduced aldosterone secretion. The primary mechanism is ACE inhibition, which decreases angiotensin II levels and subsequently reduces aldosterone-mediated sodium retention. In contrast, diuretics (e.g., thiazides, loop diuretics) directly increase sodium and water excretion by acting on the renal tubules.",
      "correct_choice_id": 248398,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72668591727680975/72668591727680975.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72668591727680975/72668591727680975.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50214,
      "choices": [
        {
          "id": 248401,
          "text": "Beta-blocker"
        },
        {
          "id": 248402,
          "text": "ACE inhibitor"
        },
        {
          "id": 248403,
          "text": "Calcium channel blocker"
        },
        {
          "id": 248404,
          "text": "Thiazide diuretic"
        }
      ],
      "text": "A 58-year-old man with a history of ischemic heart disease and hypertension is being treated with an ACE inhibitor and a beta-blocker. He is found to have worsening renal function and elevated potassium levels. Which medication should be reviewed or adjusted in his treatment plan?",
      "unique_key": "Q4076851",
      "question_audio": null,
      "question_video": null,
      "map_id": 34256397,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) ACE inhibitor. ACE inhibitors (e.g., lisinopril, enalapril) are commonly used in patients with ischemic heart disease and hypertension due to their benefits in reducing mortality, preventing remodeling, and improving cardiac function. However, ACE inhibitors can reduce renal perfusion and elevate potassium levels (hyperkalemia), particularly in patients with pre-existing renal impairment or when used in conjunction with other medications that also increase potassium levels. In this patient, the combination of worsening renal function and elevated potassium levels suggests that the ACE inhibitor may be contributing to these issues. Therefore, the ACE inhibitor should be reviewed, and dose adjustments or discontinuation should be considered. Renal function and potassium levels should be monitored closely when initiating or adjusting ACE inhibitors. Explanation of Incorrect Options: (A) Beta-blocker – Incorrect. While beta-blockers (e.g., metoprolol, atenolol) are commonly prescribed for ischemic heart disease and hypertension, they are not typically associated with worsening renal function or elevated potassium levels. Beta-blockers mainly work by reducing heart rate and blood pressure but do not have a direct effect on renal function or potassium levels. Therefore, the beta-blocker is less likely to be the cause of the patient's symptoms and does not need to be adjusted based on the information provided. (C) Calcium channel blocker – Incorrect. Calcium channel blockers (CCBs) such as amlodipine are used to manage hypertension and angina, but they are not commonly associated with worsening renal function or hyperkalemia. While CCBs may cause some fluid retention or peripheral edema, they do not typically affect renal function or potassium levels directly. In this patient, the CCB is unlikely to be responsible for the worsening renal function or elevated potassium, so it does not need to be adjusted. (D) Thiazide diuretic – Incorrect. Thiazide diuretics (e.g., hydrochlorothiazide) are often used in hypertension and can help with fluid overload. Thiazides typically lower potassium levels (hypokalemia) rather than raising them. However, the primary concern in this patient is hyperkalemia, which is not a typical side effect of thiazide diuretics. If the patient were on a potassium-sparing diuretic (e.g., spironolactone), hyperkalemia could be a concern, but thiazides would more commonly lead to hypokalemia. Therefore, thiazide diuretics are unlikely to be the cause of the elevated potassium levels and do not require adjustment in this context.",
      "correct_choice_id": 248402,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64688231727682337/64688231727682337.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64688231727682337/64688231727682337.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50215,
      "choices": [
        {
          "id": 248405,
          "text": "Increased aldosterone secretion"
        },
        {
          "id": 248406,
          "text": "Decreased renin activity"
        },
        {
          "id": 248407,
          "text": "Increased angiotensin II levels"
        },
        {
          "id": 248408,
          "text": "Decreased atrial natriuretic peptide secretion"
        }
      ],
      "text": "A 60-year-old male with hypertension is started on lisinopril. Which of the following endocrine effects can this medication have on the renin-angiotensin-aldosterone system?",
      "unique_key": "Q1655586",
      "question_audio": null,
      "question_video": null,
      "map_id": 34015089,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Decreased renin activity. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, which works by blocking the conversion of angiotensin I to angiotensin II. This leads to a reduction in angiotensin II levels, which in turn reduces aldosterone secretion from the adrenal glands. Aldosterone normally promotes sodium retention and potassium excretion, so its reduction leads to decreased sodium retention and lower blood pressure. Since angiotensin II normally suppresses renin release via negative feedback, the reduction in angiotensin II caused by lisinopril results in an initial compensatory increase in renin secretion. However, over time, the persistent blockade of the renin-angiotensin-aldosterone system (RAAS) leads to an overall decrease in renin activity due to long-term homeostatic adjustments. Explanation of Incorrect Options: (A) Increased aldosterone secretion – Incorrect. ACE inhibitors like lisinopril decrease aldosterone secretion by reducing angiotensin II production. This is beneficial in conditions like hypertension and heart failure, as lower aldosterone levels result in reduced sodium and water retention, leading to lower blood pressure. (C) Increased angiotensin II levels – Incorrect. ACE inhibitors directly inhibit the conversion of angiotensin I to angiotensin II, leading to reduced angiotensin II levels. This is a primary mechanism by which ACE inhibitors lower blood pressure. (D) Decreased atrial natriuretic peptide (ANP) secretion – Incorrect. ANP is released by the atria in response to increased blood volume and pressure. ACE inhibitors reduce blood volume and actually promote ANP release, as they lead to vasodilation and natriuresis (sodium excretion). Therefore, ANP secretion would increase, not decrease.",
      "correct_choice_id": 248406,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 50216,
      "choices": [
        {
          "id": 248409,
          "text": "Increased insulin sensitivity"
        },
        {
          "id": 248410,
          "text": "Reduction of albuminuria"
        },
        {
          "id": 248411,
          "text": "Direct vasodilation of skeletal muscles"
        },
        {
          "id": 248412,
          "text": "Stimulation of renin release"
        }
      ],
      "text": "A 55-year-old man with hypertension and diabetes is started on an ACE inhibitor. Which of the following beneficial effects does this class of drugs provide beyond blood pressure reduction?",
      "unique_key": "Q1728473",
      "question_audio": null,
      "question_video": null,
      "map_id": 34447774,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Reduction of albuminuria. Angiotensin-converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, and ramipril, are widely used in the treatment of hypertension and diabetes, particularly in patients at risk for diabetic nephropathy. These drugs work by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to reduced glomerular hypertension, which helps protect the kidneys from damage. One of the most significant benefits of ACE inhibitors in diabetic patients is their ability to reduce albuminuria (protein leakage in urine) by decreasing intraglomerular pressure. This slows the progression of diabetic nephropathy and helps preserve kidney function, making them a preferred choice in hypertensive diabetics. Explanation of Incorrect Options: A. Increased insulin sensitivity – Incorrect ACE inhibitors do not directly increase insulin sensitivity. However, some studies suggest they might have a mild beneficial effect on glucose metabolism by improving blood flow to muscles and reducing angiotensin II’s inhibitory effects on insulin signaling. Despite this, their primary benefit in diabetic patients is renal protection, not significant improvement in insulin sensitivity. C. Direct vasodilation of skeletal muscles – Incorrect ACE inhibitors primarily cause vasodilation by reducing angiotensin II levels and increasing bradykinin, leading to overall blood pressure reduction. While this can improve muscle perfusion indirectly, they do not directly cause vasodilation in skeletal muscles. Medications such as calcium channel blockers or nitrates are more directly associated with vasodilation of specific vascular beds. D. Stimulation of renin release – Incorrect ACE inhibitors actually increase renin release, but this is a compensatory effect due to the inhibition of the renin-angiotensin-aldosterone system (RAAS). However, this increase does not provide a therapeutic benefit and is not the primary reason ACE inhibitors are used in hypertension and diabetes. Instead, their key benefit lies in reducing angiotensin II-mediated vasoconstriction and kidney damage.",
      "correct_choice_id": 248410,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}